Would you consider chemoimmunotherapy (CP-Pembro-AC) in triple negative breast cancer if tumor is not palpable on physical exam?
If yes, how do you assess the tumor response and how frequently while on neoadjuvant chemoimmunotherapy?
Answer from: Medical Oncologist at Community Practice
KN522 regimen is approved for cT2 or greater (tumor >2cm) regardless of nodal involvement or cT1c with nodal involvement. The tumor size can be determined by a physical exam or radiologic assessment or both. Therefore, it is perfectly fine to use KN522 regimen if the tumor is not palpable as long...
Sign in or Register to read more